
## Raymond C Vanholder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8441717/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney International, 2003, 63, 1934-1943.	2.6	1,379

2 International Society of Nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths) Tj ETQq0 0 0 grgBT /Overlock 10 7

3	Normal and Pathologic Concentrations of Uremic Toxins. Journal of the American Society of Nephrology: JASN, 2012, 23, 1258-1270.	3.0	758
4	Acute kidney injury: an increasing global concern. Lancet, The, 2013, 382, 170-179.	6.3	752
5	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1551-1558.	2.2	740
6	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.4	628
7	Clinical practice guideline on diagnosis and treatment of hyponatraemia. European Journal of Endocrinology, 2014, 170, G1-G47.	1.9	596
8	Rhabdomyolysis. Journal of the American Society of Nephrology: JASN, 2000, 11, 1553-1561.	3.0	576
9	The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate. Journal of the American Society of Nephrology: JASN, 2014, 25, 1897-1907.	3.0	525
10	Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis Transplantation, 2005, 20, 1048-1056.	0.4	523
11	EBPG on Vascular Access. Nephrology Dialysis Transplantation, 2007, 22, ii88-ii117.	0.4	475
12	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation, 2012, 27, 4263-4272.	0.4	460
13	EBPG Guideline on Nutrition. Nephrology Dialysis Transplantation, 2007, 22, ii45-ii87.	0.4	442
14	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	2.5	434
15	The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International, 2004, 65, 442-451.	2.6	421
16	Acute renal failure. Lancet, The, 2005, 365, 417-30.	6.3	415
17	Acute Renal Failure in Patients with Sepsis in a Surgical ICU: Predictive Factors, Incidence, Comorbidity, and Outcome. Journal of the American Society of Nephrology: JASN, 2003, 14, 1022-1030.	3.0	388
18	The burden of kidney disease: Improving global outcomes. Kidney International, 2004, 66, 1310-1314.	2.6	376

#	Article	IF	CITATIONS
19	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 1183-1191.	0.4	371
20	Effect of Membrane Permeability on Survival of Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2009, 20, 645-654.	3.0	364
21	Cytokine Removal during Continuous Hemofiltration in Septic Patients. Journal of the American Society of Nephrology: JASN, 1999, 10, 846-853.	3.0	364
22	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet, The, 2014, 383, 1831-1843.	6.3	341
23	Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature*. Nephrology Dialysis Transplantation, 2013, 28, 254-273.	0.4	324
24	A Bench to Bedside View of Uremic Toxins. Journal of the American Society of Nephrology: JASN, 2008, 19, 863-870.	3.0	287
25	Management of Crush-Related Injuries after Disasters. New England Journal of Medicine, 2006, 354, 1052-1063.	13.9	281
26	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Science Translational Medicine, 2010, 2, 46ps42.	5.8	273
27	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. American Journal of Kidney Diseases, 2016, 67, 483-498.	2.1	271
28	The systemic nature of CKD. Nature Reviews Nephrology, 2017, 13, 344-358.	4.1	265
29	p-Cresyl Sulfate. Toxins, 2017, 9, 52.	1.5	262
30	P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology Dialysis Transplantation, 2006, 22, 592-596.	0.4	259
31	The current and future landscape of dialysis. Nature Reviews Nephrology, 2020, 16, 573-585.	4.1	252
32	Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrology Dialysis Transplantation, 2000, 15, 50-57.	0.4	243
33	Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. American Journal of Medicine, 2001, 110, 438-441.	0.6	242
34	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney International, 2010, 77, 550-556.	2.6	242
35	An Evaluation of an Integrative Care Approach for End-Stage Renal Disease Patients. Journal of the American Society of Nephrology: JASN, 2000, 11, 116-125.	3.0	235
36	The changing epidemiology of acute renal failure. Nature Clinical Practice Nephrology, 2006, 2, 364-377.	2.0	229

#	Article	IF	CITATIONS
37	European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care: FIGUREÂ1 Nephrology Dialysis Transplantation, 2015, 30, 1790-1797.	0.4	229
38	Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins, 2018, 10, 33.	1.5	218
39	p-Cresyl Sulfate Promotes Insulin Resistance Associated with CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 88-99.	3.0	216
40	Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrology Dialysis Transplantation, 2005, 20, 747-753.	0.4	210
41	Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrology Dialysis Transplantation, 2013, 28, 542-550.	0.4	210
42	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.4	206
43	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney International, 2013, 84, 733-744.	2.6	205
44	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	3.0	205
45	Pathophysiologic Effects of Uremic Retention Solutes. Journal of the American Society of Nephrology: JASN, 1999, 10, 1815-1823.	3.0	201
46	Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nature Reviews Nephrology, 2017, 13, 393-409.	4.1	200
47	EBPG guideline on haemodynamic instability. Nephrology Dialysis Transplantation, 2007, 22, ii22-ii44.	0.4	191
48	Prognostic Value of Aortic Stiffness and Calcification for Cardiovascular Events and Mortality in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 153-159.	2.2	191
49	Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney International, 1991, 39, 320-327.	2.6	190
50	What is new in uremic toxicity?. Pediatric Nephrology, 2008, 23, 1211-1221.	0.9	182
51	A longitudinal, five year survey of urea kinetic parameters in CAPD patients. Kidney International, 1992, 42, 426-432.	2.6	179
52	CEâ€MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics - Clinical Applications, 2008, 2, 964-973.	0.8	178
53	Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation, 2008, 24, 348-354.	0.4	178
54	EBPG guideline on dialysis strategies. Nephrology Dialysis Transplantation, 2007, 22, ii5-ii21.	0.4	175

#	Article	IF	CITATIONS
55	New insights in uremic toxins. Kidney International, 2003, 63, S6-S10.	2.6	174
56	Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 297-302.	1.1	165
57	Noninvasive Assessment of Local Pulse Pressure. Hypertension, 2005, 46, 244-248.	1.3	163
58	The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. European Heart Journal, 2007, 28, 478-483.	1.0	157
59	Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrology Dialysis Transplantation, 2008, 24, 562-570.	0.4	156
60	Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. American Journal of Kidney Diseases, 2002, 40, 339-347.	2.1	155
61	Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. American Journal of Kidney Diseases, 2004, 43, 817-824.	2.1	155
62	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
63	Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 2012, 42, 1027-1036.	1.7	151
64	Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nature Medicine, 2005, 11, 223-227.	15.2	147
65	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	6.3	147
66	Histological prevalence of β2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney International, 1997, 51, 1928-1932.	2.6	146
67	Defining Acute Renal Failure: RIFLE and Beyond: Table 1 Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1314-1319.	2.2	145
68	Management of Crush Victims in Mass Disasters. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 328-335.	2.2	143
69	Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidney International, 1988, 33, 996-1004.	2.6	142
70	When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrology Dialysis Transplantation, 2011, 26, 2082-2086.	0.4	140
71	Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney International, 1995, 47, 510-517.	2.6	139
72	Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E–Deficient Mice. Circulation, 2005, 112, 2875-2882.	1.6	139

#	Article	IF	CITATIONS
73	PROGRESS IN UREMIC TOXIN RESEARCH: Proteinâ€Bound Toxins—Update 2009. Seminars in Dialysis, 2009, 22, 334-339.	0.7	139
74	The Gut: The Forgotten Organ in Uremia?. Blood Purification, 2010, 29, 130-136.	0.9	139
75	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrology Dialysis Transplantation, 2010, 25, 2846-2850.	0.4	137
76	Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney International, 2012, 82, 1297-1303.	2.6	134
77	An update on uremic toxins. International Urology and Nephrology, 2013, 45, 139-150.	0.6	134
78	Association of Dialysate Bicarbonate Concentration With Mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 2013, 62, 738-746.	2.1	133
79	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.4	133
80	Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. Kidney International, 2020, 97, 1230-1242.	2.6	125
81	Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrology Dialysis Transplantation, 2009, 24, 1429-1435.	0.4	124
82	Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)*. Nephrology Dialysis Transplantation, 2012, 27, 3736-3745.	0.4	124
83	Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma. Biomaterials, 2013, 34, 7819-7828.	5.7	124
84	Urea and chronic kidney disease: the comeback of the century? (in uraemia research). Nephrology Dialysis Transplantation, 2018, 33, 4-12.	0.4	122
85	An overview of morbidity and mortality in patients with acute renal failure due to crush syndrome: the Marmara earthquake experience. Nephrology Dialysis Transplantation, 2002, 17, 33-40.	0.4	121
86	Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrology Dialysis Transplantation, 2004, 19, 3068-3077.	0.4	121
87	Reimbursement of Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1291-1298.	3.0	121
88	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2374-2383.	2.2	119
89	Human Cytomegalovirus and Kidney Transplantation: A Clinician's Update. American Journal of Kidney Diseases, 2011, 58, 118-126.	2.1	118
90	Clinical Evidence on Hemodiafiltration: A Systematic Review and a Metaâ€analysis. Seminars in Dialysis, 2014, 27, 119-127.	0.7	117

#	Article	IF	CITATIONS
91	Associations of Self-Reported Physical Activity Types and Levels with Quality of Life, Depression Symptoms, and Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1702-1712.	2.2	117
92	Toxicity of Free p-Cresol: A Prospective and Cross-Sectional Analysis. Clinical Chemistry, 2003, 49, 470-478.	1.5	114
93	Kinetic behavior of urea is different from that of other water-soluble compounds: The case of the guanidino compounds. Kidney International, 2005, 67, 1566-1575.	2.6	113
94	Acute kidney injury. Lancet, The, 2008, 372, 1863-1865.	6.3	111
95	Adequacy of dialysis: A critical analysis. Kidney International, 1992, 42, 540-558.	2.6	108
96	New-Onset Diabetes After Renal Transplantation. Diabetes Care, 2012, 35, 181-188.	4.3	105
97	PROGRESS IN UREMIC TOXIN RESEARCH: Guanidino Compounds as Uremic (Neuro)Toxins. Seminars in Dialysis, 2009, 22, 340-345.	0.7	103
98	Hypomagnesemia and the Risk of Death and GFR Decline in Chronic Kidney Disease. American Journal of Medicine, 2013, 126, 825-831.	0.6	103
99	Proteomic biomarkers in kidney disease: issues in development and implementation. Nature Reviews Nephrology, 2015, 11, 221-232.	4.1	101
100	p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrology Dialysis Transplantation, 1999, 14, 2813-2815.	0.4	100
101	Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients. Journal of Proteome Research, 2009, 8, 335-345.	1.8	98
102	Comparison of different equations to assess glomerular filtration in critically ill patients. Intensive Care Medicine, 2015, 41, 427-435.	3.9	98
103	The Marmara earthquake: Epidemiological analysis of the victims with nephrological problems. Kidney International, 2001, 60, 1114-1123.	2.6	97
104	Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrology Dialysis Transplantation, 2012, 27, 2388-2396.	0.4	97
105	Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrology Dialysis Transplantation, 2002, 17, 1942-1949.	0.4	96
106	Aortic Stiffness and Central Wave Reflections Predict Outcome in Renal Transplant Recipients. Hypertension, 2011, 58, 833-838.	1.3	96
107	Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. Journal of the American Society of Nephrology: JASN, 2013, 24, 1981-1994.	3.0	96
108	Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. Journal of Nephrology, 2005, 18, 54-60.	0.9	96

#	Article	IF	CITATIONS
109	Delayed gastric emptying in dyspeptic chronic hemodialysis patients. American Journal of Kidney Diseases, 2000, 36, 962-968.	2.1	95
110	Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study. Critical Care, 2016, 20, 256.	2.5	94
111	Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. Nephrology Dialysis Transplantation, 2019, 34, ii1-ii42.	0.4	94
112	A sensitive HPLC method for the quantification of free and total p -cresol in patients with chronic renal failure. Clinica Chimica Acta, 1998, 278, 1-21.	0.5	93
113	The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrology Dialysis Transplantation, 2006, 21, 77-83.	0.4	93
114	Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrology Dialysis Transplantation, 2007, 22, 2006-2012.	0.4	93
115	Recommendations for the Management of Crush Victims in Mass Disasters. Nephrology Dialysis Transplantation, 2012, 27, i1-i67.	0.4	93
116	Tumor Necrosis Factor Receptors: Biology and Therapeutic Potential in Kidney Diseases. American Journal of Nephrology, 2012, 36, 261-270.	1.4	93
117	In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney International, 2004, 65, 2184-2192.	2.6	92
118	Body Composition, Hydration, and Related Parameters in Hemodialysis versus Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2010, 30, 208-214.	1.1	91
119	Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrology Dialysis Transplantation, 2011, 26, 2624-2630.	0.4	91
120	Hemoglobin A1c Levels and Mortality in the Diabetic Hemodialysis Population. Diabetes Care, 2012, 35, 2527-2532.	4.3	89
121	Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?. Nephrology Dialysis Transplantation, 2014, 29, 2167-2177.	0.4	89
122	Organ donation and transplantation: a multi-stakeholder call to action. Nature Reviews Nephrology, 2021, 17, 554-568.	4.1	89
123	P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney International, 2002, 62, 1999-2009.	2.6	88
124	Diquat intoxication. American Journal of Medicine, 1981, 70, 1267-1271.	0.6	87
125	Effect of Nosocomial Bloodstream Infection on the Outcome of Critically III Patients with Acute Renal Failure Treated with Renal Replacement Therapy. Journal of the American Society of Nephrology: JASN, 2004, 15, 454-462.	3.0	86
126	Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrology Dialysis Transplantation, 2011, 26, 1464-1467.	0.4	86

#	Article	IF	CITATIONS
127	Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110.	1.3	86
128	P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thrombosis and Haemostasis, 2004, 92, 140-150.	1.8	85
129	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrology Dialysis Transplantation, 2010, 25, 3823-3831.	0.4	85
130	Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrology Dialysis Transplantation, 2010, 25, 2052-2062.	0.4	85
131	Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. American Journal of Kidney Diseases, 1999, 33, 934-940.	2.1	84
132	Epidemiologic Aspects of the Bam Earthquake in Iran: The Nephrologic Perspective. American Journal of Kidney Diseases, 2006, 47, 428-438.	2.1	83
133	The intestine and the kidneys: a bad marriage can be hazardous. CKJ: Clinical Kidney Journal, 2015, 8, 168-179.	1.4	82
134	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrology Dialysis Transplantation, 2015, 30, 1028-1037.	0.4	81
135	Complex Compartmental Behavior of Small Water-Soluble Uremic Retention Solutes: Evaluation by Direct Measurements in Plasma and Erythrocytes. American Journal of Kidney Diseases, 2007, 50, 279-288.	2.1	80
136	Estimated Glomerular Filtration Rate Is a Poor Predictor of Concentration for a Broad Range of Uremic Toxins. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1266-1273.	2.2	79
137	Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrology Dialysis Transplantation, 2013, 28, 505-517.	0.4	79
138	Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, 1956-1964.	0.4	79
139	Urinary output and fractional excretion of sodium and urea as indicators of transient versus intrinsic acute kidney injury during early sepsis. Critical Care, 2013, 17, R234.	2.5	78
140	Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes and Endocrinology,the, 2016, 4, 360-373.	5.5	78
141	Protein-bound uremic solutes: The forgotten toxins. Kidney International, 2001, 59, S266-S270.	2.6	77
142	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrology Dialysis Transplantation, 2010, 25, 2672-2679.	0.4	77
143	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrology Dialysis Transplantation, 2011, 26, 2099-2106.	0.4	77
144	p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrology Dialysis Transplantation, 2014, 29, 56-64.	0.4	77

#	Article	IF	CITATIONS
145	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney International Reports, 2017, 2, 1066-1075.	0.4	77
146	The role of trace elements in uraemic toxicity. Nephrology Dialysis Transplantation, 2002, 17, 2-8.	0.4	76
147	A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application, Nephrology Dialysis Transplantation, 2014, 29, 490-496.	0.4	76
148	Acute renal failure related to the crush syndrome: towards an era of seismoâ€nephrology?. Nephrology Dialysis Transplantation, 2000, 15, 1517-1521.	0.4	75
149	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrology Dialysis Transplantation, 2007, 22, 3381-3390.	0.4	74
150	Classification of Uremic Toxins and Their Role in Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1918-1928.	2.2	74
151	Intervention of the Renal Disaster Relief Task Force in the 1999 Marmara, Turkey earthquake. Kidney International, 2001, 59, 783-791.	2.6	73
152	The Rise of Prevalence and the Fall of Mortality of Patients with Acute Renal Failure: What the Analysis of Two Databases Does and Does Not Tell Us. Journal of the American Society of Nephrology: JASN, 2006, 17, 923-925.	3.0	73
153	Future Avenues to Decrease Uremic Toxin Concentration. American Journal of Kidney Diseases, 2016, 67, 664-676.	2.1	72
154	Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrologie Et Therapeutique, 2014, 10, 463-470.	0.2	71
155	An International Analysis of Dialysis Services Reimbursement. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 84-93.	2.2	71
156	Survival and Complications of Indwelling Venous Catheters for Permanent Use in Hemodialysis Patients. Artificial Organs, 2005, 29, 399-405.	1.0	70
157	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. Nephrology Dialysis Transplantation, 2013, 28, 2940-2945.	0.4	70
158	Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nature Reviews Nephrology, 2021, 17, 528-542.	4.1	70
159	Mortality risk in patients on hemodiafiltration versus hemodialysis: a â€~real-world' comparison from the DOPPS. Nephrology Dialysis Transplantation, 2018, 33, 683-689.	0.4	69
160	Catheter-related blood stream infections (CRBSI): a European view. Nephrology Dialysis Transplantation, 2010, 25, 1753-1756.	0.4	68
161	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney International, 2013, 84, 1237-1245.	2.6	67
162	Once upon a time in dialysis: the last days of Kt/V?. Kidney International, 2015, 88, 460-465.	2.6	67

#	Article	IF	CITATIONS
163	Prospective Evaluation of the Change of Predialysis Proteinâ€Bound Uremic Solute Concentration With Postdilution Online Hemodiafiltration. Artificial Organs, 2010, 34, 580-585.	1.0	66
164	Which dialyser membrane to choose?. Nephrology Dialysis Transplantation, 2004, 19, 293-296.	0.4	64
165	Does the Adequacy Parameter Kt/Vurea Reflect Uremic Toxin Concentrations in Hemodialysis Patients?. PLoS ONE, 2013, 8, e76838.	1.1	64
166	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrology Dialysis Transplantation, 2015, 30, 1842-1852.	0.4	64
167	Acute kidney injury in critically ill cancer patients: an update. Critical Care, 2016, 20, 209.	2.5	64
168	Reevaluation of Formulas for Predicting Creatinine Clearance in Adults and Children, Using Compensated Creatinine Methods. Clinical Chemistry, 2003, 49, 1011-1014.	1.5	63
169	Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101.	1.3	63
170	Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis. Kidney International, 1994, 45, 1754-1759.	2.6	62
171	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrology Dialysis Transplantation, 2017, 32, gfw337.	0.4	62
172	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. Nephrology Dialysis Transplantation, 2016, 31, 691-697.	0.4	62
173	Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure forÂHemodialysis Vascular Access. American Journal of Kidney Diseases, 2018, 71, 690-700.	2.1	62
174	Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Scientific Reports, 2019, 9, 4477.	1.6	62
175	Uraemic toxins and cardiovascular disease. Nephrology Dialysis Transplantation, 2003, 18, 463-466.	0.4	61
176	Chronic kidney disease in adults—UK guidelines for identification, management and referral. Nephrology Dialysis Transplantation, 2006, 21, 1776-1777.	0.4	61
177	Epidemiology of infection in critically ill patients with acute renal failure. Critical Care Medicine, 2009, 37, 2203-2209.	0.4	60
178	Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?. PLoS ONE, 2013, 8, e67168.	1.1	60
179	Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 1850-1855.	0.4	59
180	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrology Dialysis Transplantation, 2008, 23, 2162-2166.	0.4	59

#	Article	IF	CITATIONS
181	Soluble Tumor Necrosis Factor Receptor 1 and 2 Predict Outcomes in Advanced Chronic Kidney Disease: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0122073.	1.1	59
182	Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients: A Prospective Longâ€Term Study. Journal of Parenteral and Enteral Nutrition, 1999, 23, 90-95.	1.3	58
183	Renal replacement therapies in the aftermath of the catastrophic Marmara earthquake. Kidney International, 2002, 62, 2264-2271.	2.6	58
184	Prevention and nondialytic treatment of acute renal failure. Current Opinion in Critical Care, 2003, 9, 481-490.	1.6	58
185	New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Scientific Reports, 2016, 6, 34429.	1.6	58
186	Outcome in a post-cardiac surgery population with acute renal failure requiring dialysis: does age make a difference?. Nephrology Dialysis Transplantation, 2003, 18, 732-736.	0.4	57
187	Delayed graft function in renal transplantation. Current Opinion in Critical Care, 2004, 10, 489-498.	1.6	57
188	Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. Nephrology Dialysis Transplantation, 2011, 26, 955-963.	0.4	57
189	Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2018, 33, 2234-2244.	0.4	57
190	Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney International, 2003, 63, 1764-1775.	2.6	56
191	Features of Chronic Hemodialysis Practice after the Marmara Earthquake. Journal of the American Society of Nephrology: JASN, 2004, 15, 1071-1076.	3.0	56
192	Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676.	0.3	56
193	Sodium bicarbonate versus THAM in ICU patients with mild metabolic acidosis. Journal of Nephrology, 2005, 18, 303-7.	0.9	56
194	Prevalence of histological β2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney International, 1998, 54, 956-959.	2.6	55
195	Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: Role of nitric oxide. Kidney International, 2001, 60, 202-210.	2.6	55
196	How to use biomarkers efficiently in acute kidney injury. Kidney International, 2011, 79, 1047-1050.	2.6	55
197	In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney International, 2004, 66, 1873-1880.	2.6	53
198	Inconsistency of Reported Uremic Toxin Concentrations. Artificial Organs, 2007, 31, 600-611.	1.0	53

#	ARTICLE	IF	CITATIONS
199	Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). CKJ: Clinical Kidney Journal, 2010, 3, 234-246.	1.4	53
200	AST-120 for the management of progression of chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 2014, 7, 49.	0.8	53
201	The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?. Journal of Nephrology, 2008, 21, 146-60.	0.9	53
202	Identification of some arsenic species in human urine and blood after ingestion of Chinese seaweed Laminaria. Journal of Analytical Atomic Spectrometry, 2004, 19, 58.	1.6	52
203	Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. Frontiers in Medicine, 2015, 2, 60.	1.2	52
204	Protein-bound uraemic toxins, dicarbonyl stress and advanced glycation end products in conventional and extended haemodialysis and haemodiafiltration. Nephrology Dialysis Transplantation, 2015, 30, 1395-1402.	0.4	52
205	Loop Diuretics for Patients With Acute Renal Failure. JAMA - Journal of the American Medical Association, 2002, 288, 2599.	3.8	51
206	Correction of Deficient Phagocytosis During Erythropoietin Treatment in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 1992, 19, 358-363.	2.1	50
207	Efficacy of Erythropoietin Administration in the Treatment of Anemia Immediately After Renal Transplantation. Transplantation, 2005, 79, 367-368.	0.5	50
208	Did 20 Years of Technological Innovations in Hemodialysis Contribute to Better Patient Outcomes?. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, S30-S40.	2.2	50
209	Electrolyte Disturbances and Acute Kidney Injury in Patients With Cancer. Seminars in Nephrology, 2010, 30, 534-547.	0.6	50
210	Renal Disaster Relief Task Force in Haiti earthquake. Lancet, The, 2010, 375, 1162-1163.	6.3	50
211	Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography. Journal of Biological Inorganic Chemistry, 2002, 7, 884-890.	1.1	49
212	Review on uraemic solutes II Variability in reported concentrations: causes and consequences. Nephrology Dialysis Transplantation, 2007, 22, 3115-3121.	0.4	49
213	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. Blood Purification, 2010, 30, 277-287.	0.9	49
214	Lessons learned from the Marmara disaster: Time period under the rubble. Critical Care Medicine, 2002, 30, 2443-2449.	0.4	48
215	Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone, 2007, 41, 698-703.	1.4	48
216	Studies on dialysate mixing in the Genius® single-pass batch system for hemodialysis therapy. Kidney International, 2003, 63, 1540-1547.	2.6	47

#	Article	IF	CITATIONS
217	Biochemical and Clinical Evidence for Uremic Toxicity. Artificial Organs, 2004, 28, 248-253.	1.0	47
218	The Personal Dialysis Capacity Test Is Superior to the Peritoneal Equilibration Test to Discriminate Inflammation as the Cause of Fast Transport Status in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 269-274.	2.2	47
219	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clinica Chimica Acta, 2007, 379, 87-94.	0.5	47
220	A novel UPLC–MS–MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Analytical and Bioanalytical Chemistry, 2013, 405, 1937-1947.	1.9	47
221	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	1.3	47
222	Treatment Modalities and Outcome of the Renal Victims of the Marmara Earthquake. Nephron, 2002, 92, 64-71.	0.9	46
223	Renal disaster relief: from theory to practice. Nephrology Dialysis Transplantation, 2009, 24, 1730-1735.	0.4	46
224	Disaster nephrology: a new concept for an old problem. CKJ: Clinical Kidney Journal, 2015, 8, 300-309.	1.4	46
225	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. Nephrology Dialysis Transplantation, 2018, 33, 2156-2164.	0.4	46
226	Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney International, 1993, 44, 208-214.	2.6	45
227	Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?. Critical Care, 2010, 15, 204.	2.5	45
228	Dialysis water and fluid purity: more than endotoxin. Nephrology Dialysis Transplantation, 2012, 27, 4010-4021.	0.4	45
229	Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions. Nature Reviews Nephrology, 2012, 8, 542-550.	4.1	45
230	Disaster nephrology: crush injury and beyond. Kidney International, 2014, 85, 1049-1057.	2.6	45
231	Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis. PLoS ONE, 2016, 11, e0147159.	1.1	45
232	Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney International, 1991, 40, 868-873.	2.6	44
233	The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrology Dialysis Transplantation, 2011, 26, 2362-2369.	0.4	44
234	Epidemiology of acute kidney injury in children worldwide, including developing countries. Pediatric Nephrology, 2017, 32, 1301-1314.	0.9	44

#	Article	IF	CITATIONS
235	Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease. Toxins, 2013, 5, 2058-2073.	1.5	43
236	PROGRESS IN UREMIC TOXIN RESEARCH: Platelet/Leukocyte Activation, Inflammation, and Uremia. Seminars in Dialysis, 2009, 22, 423-427.	0.7	42
237	Hypomagnesaemia, the kidney and the vessels. Nephrology Dialysis Transplantation, 2012, 27, 4003-4010.	0.4	42
238	Association between changes in quality of life and mortality in hemodialysis patients: results from the DOPPS. Nephrology Dialysis Transplantation, 2017, 32, gfw233.	0.4	42
239	Cost of renal replacement: how to help as many as possible while keeping expenses reasonable?. Nephrology Dialysis Transplantation, 2016, 31, 1251-1261.	0.4	42
240	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrology Dialysis Transplantation, 2008, 24, 719-727.	0.4	41
241	An Update on Protein-Bound Uremic Retention Solutes. , 2012, 22, 90-94.		41
242	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. American Journal of Kidney Diseases, 2018, 71, 382-391.	2.1	41
243	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. CKJ: Clinical Kidney Journal, 2021, 14, 1719-1730.	1.4	41
244	Dialysing the patient with acute renal failure in the ICU: the emperor's clothes?. Nephrology Dialysis Transplantation, 1999, 14, 2570-2573.	0.4	40
245	Acute renal failure due to crush syndrome during Marmara earthquake. American Journal of Kidney Diseases, 2002, 40, 682-689.	2.1	40
246	Arterial stiffness and wave reflections in renal transplant recipients. Nephrology Dialysis Transplantation, 2007, 22, 3021-3027.	0.4	40
247	Acute renal problems in the critically ill cancer patient. Current Opinion in Critical Care, 2008, 14, 635-646.	1.6	40
248	Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. Nephrology Dialysis Transplantation, 2009, 24, 2225-2232.	0.4	40
249	Biology of Human Pentraxin 3 (PTX3) in Acute and Chronic Kidney Disease. Journal of Clinical Immunology, 2013, 33, 881-890.	2.0	40
250	Cuprophan reuse and intradialytic changes of lung diffusion capacity and blood gasses. Kidney International, 1987, 32, 117-122.	2.6	38
251	Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. International Journal of Cardiology, 2013, 167, 2555-2560.	0.8	38
252	The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transplant International, 2014, 27, 895-902.	0.8	38

#	Article	IF	CITATIONS
253	Therapeutic Interventions Favorably Influencing Delayed and Slow Graft Function in Kidney Transplantation: Mission Impossible?. Transplantation, 2008, 85, S31-S37.	0.5	37
254	A Sad but Forgotten Truth: The Story of Slowâ€Moving Solutes in Fast Hemodialysis. Seminars in Dialysis, 2012, 25, 505-509.	0.7	37
255	Gut microbiota dynamics and uraemic toxins: one size does not fit all. Gut, 2019, 68, 2257.1-2260.	6.1	37
256	Binding of indole-3-acetic acid to human serum albumin and competition with l-tryptophan. Clinica Chimica Acta, 1997, 265, 183-192.	0.5	35
257	Urinary excretion of the uraemic toxin p-cresol in the rat: contribution of glucuronidation to its metabolization. Nephrology Dialysis Transplantation, 2003, 18, 1299-1306.	0.4	35
258	New Uremic Toxins – Which Solutes Should Be Removed?. Contributions To Nephrology, 2011, 168, 117-128.	1.1	35
259	Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study. Critical Care, 2015, 19, 289.	2.5	34
260	The biological action of calcitriol in renal failure. Kidney International, 1994, 46, 605-612.	2.6	33
261	The MPO Study: Just a European HEMO Study or Something Very Different?. Blood Purification, 2008, 26, 100-104.	0.9	33
262	Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum. Clinical Chemistry, 2009, 55, 1431-1433.	1.5	33
263	In Vitro Methylation of Arsenite by Rabbit Liver Cytosol: Effect of Metal Ions, Metal Chelating Agents, Methyltransferase Inhibitors and Uremic Toxins. Drug and Chemical Toxicology, 1999, 22, 613-628.	1.2	32
264	Uremic Toxins: Do We Know Enough to Explain Uremia?. Blood Purification, 2008, 26, 77-81.	0.9	32
265	Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?. Nature Reviews Nephrology, 2009, 5, 130-131.	4.1	32
266	The cell cycle biomarkers: promising research, but do not oversell them. CKJ: Clinical Kidney Journal, 2016, 9, 353-358.	1.4	32
267	Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study. Analytical and Bioanalytical Chemistry, 2017, 409, 2201-2211.	1.9	32
268	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrology Dialysis Transplantation, 2018, 33, 1661-1668.	0.4	32
269	Free <i>p</i> -cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 998-1005.	0.4	32
270	Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrology Dialysis Transplantation, 2006, 22, 53-58.	0.4	31

#	Article	IF	CITATIONS
271	Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrology Dialysis Transplantation, 2007, 23, 294-300.	0.4	31
272	Why less success of the peritoneal dialysis programmes in Europe?. Nephrology Dialysis Transplantation, 2008, 23, 1478-1481.	0.4	31
273	Renal replacement therapy for refugees with end-stage kidney disease: an international survey of the nephrological community. Kidney International Supplements, 2016, 6, 35-41.	4.6	31
274	Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. Kidney International, 2021, 100, 182-195.	2.6	31
275	Impact of the Uremic Milieu on the Osteogenic Potential of Mesenchymal Stem Cells. PLoS ONE, 2015, 10, e0116468.	1.1	31
276	Pain at the Injection Site of Subcutaneously Administered Erythropoietin in Maintenance Hemodialysis Patients: A Comparison of Two Brands of Erythropoietin. American Journal of Nephrology, 1992, 12, 68-72.	1.4	30
277	Does biocompatibility of dialysis membranes affect recovery of renal function and survival?. Lancet, The, 1999, 354, 1316-1318.	6.3	30
278	Uremic toxins and peritoneal dialysis. Kidney International, 2001, 59, S292-S297.	2.6	30
279	Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch–Schönlein purpura nephritis. Clinical Biochemistry, 2013, 46, 591-597.	0.8	30
280	Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study. Peritoneal Dialysis International, 2015, 35, 436-442.	1.1	30
281	Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney International, 1994, 46, 129-133.	2.6	29
282	Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease. International Journal of Health Care Finance and Economics, 2007, 7, 133-148.	1.2	29
283	A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrology Dialysis Transplantation, 2008, 24, 548-554.	0.4	29
284	Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease. PLoS ONE, 2012, 7, e44201.	1.1	29
285	New Methods and Technologies for Measuring Uremic Toxins and Quantifying Dialysis Adequacy. Seminars in Dialysis, 2015, 28, 114-124.	0.7	29
286	Subclinical AKI: ready for primetime in clinical practice?. Journal of Nephrology, 2019, 32, 9-16.	0.9	29
287	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. Kidney International Supplements, 2021, 11, e106-e118.	4.6	29
288	Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. Nephrology Dialysis Transplantation, 2004, 19, v41-v45.	0.4	28

#	Article	IF	CITATIONS
289	What can the dialysis physician learn from kinetic modelling beyond Kt/Vurea?. Nephrology Dialysis Transplantation, 2012, 27, 4021-4029.	0.4	28
290	Severity of sepsis-induced acute kidney injury in a novel mouse model is age dependent*. Critical Care Medicine, 2012, 40, 2638-2646.	0.4	28
291	Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. Circulation Journal, 2016, 80, 722-730.	0.7	28
292	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology Dialysis Transplantation, 2018, 33, 563-573.	0.4	28
293	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). Toxins, 2018, 10, 237.	1.5	28
294	Radiochemical determination of twelve trace elements in human blood serum. Analytica Chimica Acta, 1992, 257, 1-5.	2.6	27
295	Chemical speciation of arsenic in serum of uraemic patientsâ€. Analyst, The, 1998, 123, 13-17.	1.7	27
296	Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. Journal of Chromatography A, 1999, 847, 141-153.	1.8	27
297	Comparison of survival on CAPD and haemodialysis: statistical pitfalls. Nephrology Dialysis Transplantation, 2000, 15, 307-311.	0.4	27
298	Detection of Angiotensin II in Supernatants of Stimulated Mononuclear Leukocytes by Matrix-Assisted Laser Desorption Ionization Time-of-Flight/Time-of-Flight Mass Analysis. Hypertension, 2005, 46, 591-597.	1.3	27
299	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. Seminars in Dialysis, 2009, 22, 323-328.	0.7	27
300	Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats. Nephrology Dialysis Transplantation, 2010, 25, 1688-1696.	0.4	27
301	Continuous Ambulatory Peritoneal Dialysis Peritonitis due to Enterococcus cecorum. Journal of Clinical Microbiology, 2000, 38, 3511-3512.	1.8	27
302	Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. Nephrology Dialysis Transplantation, 2007, 23, 1330-1335.	0.4	26
303	Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury. Journal of Nephrology, 2015, 28, 709-716.	0.9	26
304	Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. Toxins, 2016, 8, 149.	1.5	26
305	Caring for Migrants and Refugees With End-Stage Kidney Disease in Europe. American Journal of Kidney Diseases, 2018, 71, 701-709.	2.1	26
306	A swan song for Kt/V <sub>urea</sub> . Seminars in Dialysis, 2019, 32, 424-437.	0.7	26

#	Article	IF	CITATIONS
307	Ethical challenges in nephrology: a call for action. Nature Reviews Nephrology, 2020, 16, 603-613.	4.1	26
308	The Marmara earthquake: admission laboratory features of patients with nephrological problems. Nephrology Dialysis Transplantation, 2002, 17, 1025-1031.	0.4	25
309	An Overview of Uremic Toxicity. Hemodialysis International, 2003, 7, 156-161.	0.4	25
310	What Is Uremia? Retention versus Oxidation. Blood Purification, 2006, 24, 33-38.	0.9	25
311	Impact of local circumstances on outcome of renal casualties in major disasters. Nephrology Dialysis Transplantation, 2008, 24, 907-912.	0.4	25
312	Progress in Uremic Toxin Research: Genetics/Genomics in Chronic Kidney Disease—Towards Personalized Medicine?. Seminars in Dialysis, 2009, 22, 417-422.	0.7	25
313	Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders?. Nephrology Dialysis Transplantation, 2015, 30, 943-951.	0.4	25
314	Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. International Urology and Nephrology, 2019, 51, 293-302.	0.6	25
315	Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients. PLoS ONE, 2017, 12, e0186010.	1.1	25
316	Disturbed host defense in peritoneal cavity during CAPD: Characterization of responsible factors in dwell fluid. Kidney International, 1996, 50, 643-652.	2.6	24
317	Kinetics of the protein-bound, lipophilic, uremic toxin p-cresol in healthy rats. Life Sciences, 2001, 69, 2237-2248.	2.0	24
318	The organization and interventions of the ISN Renal Disaster Relief Task Force. Advances in Chronic Kidney Disease, 2003, 10, 93-99.	2.2	24
319	Do we need new indicators of dialysis adequacy based on middle-molecule removal?. Nature Clinical Practice Nephrology, 2008, 4, 174-175.	2.0	24
320	Educating end-stage renal disease patients on dialysis modality selection. CKJ: Clinical Kidney Journal, 2010, 3, 225-233.	1.4	24
321	Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrology Dialysis Transplantation, 2012, 27, 548-556.	0.4	24
322	Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-SchĶnlein purpura nephritis. BBA Clinical, 2016, 5, 79-84.	4.1	24
323	p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance. Nephrology Dialysis Transplantation, 2017, 32, 2000-2009.	0.4	24
324	How to increase kidney transplant activity throughout Europe—an advocacy review by the European Kidney Health Alliance. Nephrology Dialysis Transplantation, 2019, 34, 1254-1261.	0.4	24

#	Article	IF	CITATIONS
325	Pathophysiology, Causes, and Prognosis of Acute Renal Failure in the Elderly. Renal Failure, 1996, 18, 333-346.	0.8	23
326	Peritoneal-dialysis-related peritonitis: the art of rope-dancing. Nephrology Dialysis Transplantation, 2002, 17, 1878-1882.	0.4	23
327	De novo Thrombotic Microangiopathy Induced by Cytomegalovirus Infection Leading to Renal Allograft Loss. American Journal of Nephrology, 2010, 32, 491-496.	1.4	23
328	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. Hypertension, 2015, 66, 3-9.	1.3	23
329	Removal of water-soluble and protein-bound solutes with reversed mid-dilution versus post-dilution haemodiafiltration. Nephrology Dialysis Transplantation, 2012, 27, 3278-3283.	0.4	22
330	Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 657-668.	0.4	22
331	Expanding Utilization of Home Dialysis: An Action Agenda From the First International Home Dialysis Roundtable. Kidney Medicine, 2021, 3, 635-643.	1.0	22
332	Evolution of protein-bound uraemic solutes during predilution haemofiltration. Journal of Nephrology, 2009, 22, 352-7.	0.9	22
333	Peritoneal Dialysis in Europe: An Analysis of Its Rise and Fall. Blood Purification, 2006, 24, 107-114.	0.9	21
334	Severe lactic acidosis in critically ill patients with acute kidney injury treated with renal replacement therapy. Journal of Critical Care, 2014, 29, 650-655.	1.0	21
335	Early and asymptomatic cardiac dysfunction in chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 450-458.	0.4	21
336	Points of Concern in Post Acute Kidney Injury Management. Nephron, 2018, 138, 92-103.	0.9	21
337	Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease. Toxins, 2018, 10, 520.	1.5	21
338	Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease. Scientific Reports, 2019, 9, 10236.	1.6	21
339	Disasters, children and the kidneys. Pediatric Nephrology, 2020, 35, 1381-1393.	0.9	21
340	Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Medicine, 2020, 2, 286-296.	1.0	21
341	The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance. Nephrology Dialysis Transplantation, 2023, 38, 1080-1088.	0.4	21
342	Novel Frameshift Mutation in a Heterozygous Woman with Fabry Disease and End-Stage Renal Failure. American Journal of Nephrology, 1996, 16, 352-357.	1.4	20

#	Article	IF	CITATIONS
343	HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump. Kidney International, 1997, 51, 1042-1052.	2.6	20
344	Estimation of parameters in a two-pool urea kinetic model for hemodialysis. Medical Engineering and Physics, 1997, 19, 69-76.	0.8	20
345	Dissociation Between Dialysis Adequacy andKt/V. Seminars in Dialysis, 2002, 15, 3-7.	0.7	20
346	Clinical Studies and Chronic Kidney Disease: What Did we Learn Recently?. Seminars in Nephrology, 2014, 34, 164-179.	0.6	20
347	Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population. Toxins, 2019, 11, 235.	1.5	20
348	Early detection of patients at high risk for acute kidney injury during disasters: development of a scoring system based on the Bam earthquake experience. Journal of Nephrology, 2008, 21, 776-82.	0.9	20
349	What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis. Toxins, 2022, 14, 221.	1.5	20
350	Peritoneal dialysis catheters: the beauty of simplicity or the glamour of technicality? Percutaneous vs surgical placement. Nephrology Dialysis Transplantation, 2002, 17, 210-212.	0.4	19
351	Exploring the Uremic Toxins Using Proteomic Technologies. , 2008, 160, 159-171.		19
352	Renal disaster relief in Europe: the experience at L'Aquila, Italy, inÂApril 2009. Nephrology Dialysis Transplantation, 2009, 24, 3251-3255.	0.4	19
353	Flow cytometric calcium flux assay: Evaluation of cytoplasmic calcium kinetics in whole blood leukocytes. Journal of Immunological Methods, 2009, 348, 74-82.	0.6	19
354	Serum urea concentration is probably not related to outcome in ICU patients with AKI and renal replacement therapy. Nephrology Dialysis Transplantation, 2011, 26, 3211-3218.	0.4	19
355	Is Starting Hemodialysis on a Twice-Weekly Regimen a Valid Option?. American Journal of Kidney Diseases, 2014, 64, 165-167.	2.1	19
356	Mass Disasters and Burnout in Nephrology Personnel. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 829-837.	2.2	19
357	Uremic encephalopathy. Kidney International, 2022, 101, 227-241.	2.6	19
358	Middle Molecules: Toxicity and Removal by Hemodialysis and Related Strategies. Artificial Organs, 1995, 19, 1120-1125.	1.0	18
359	Vitamin E–bonded cellulose membrane and hemodialysis bioincompatibility: Absence of an acute benefit on expression of leukocyte surface molecules. American Journal of Kidney Diseases, 2000, 36, 1140-1146.	2.1	18
360	Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. Nephrology Dialysis Transplantation, 2006, 21, 2834-2840.	0.4	18

#	Article	IF	CITATIONS
361	Online Hemodiafiltration. Artificial Organs, 2006, 30, 579-585.	1.0	18
362	Uraemic toxins for consideration by the cardiologist—Beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis, 2010, 211, 381-383.	0.4	18
363	Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial. PLoS ONE, 2015, 10, e0128634.	1.1	18
364	Patient-reported factors influencing the choice of their kidney replacement treatment modality. Nephrology Dialysis Transplantation, 2022, 37, 477-488.	0.4	18
365	Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Peritoneal Dialysis International, 2002, 22, 32-8.	1.1	18
366	Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest?. Journal of Nephrology, 2008, 21, 299-304.	0.9	18
367	Continuing kidney care in conflicts. Nature Reviews Nephrology, 2022, 18, 479-480.	4.1	18
368	Right atrial thrombus in an asymptomatic hemodialysis patient with malfunctioning catheter and patent foramen ovale. Hemodialysis International, 2005, 9, 236-240.	0.4	17
369	Marconi Revisited. Journal of the American Society of Nephrology: JASN, 2008, 19, 1253-1255.	3.0	17
370	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrology Dialysis Transplantation, 2008, 23, 4044-4048.	0.4	17
371	Acute Central Hemodynamic Effects of a Volume Exchange in Peritoneal Dialysis. Peritoneal Dialysis International, 2008, 28, 142-148.	1.1	17
372	Hurricane Katrina and chronic dialysis patients: better tidings than originally feared?. Kidney International, 2009, 76, 687-689.	2.6	17
373	Acute Kidney Injury in Active Wars and Other Man-Made Disasters. Seminars in Nephrology, 2020, 40, 341-353.	0.6	17
374	Difference in Profiles of the Gut-Derived Tryptophan Metabolite Indole Acetic Acid between Transplanted and Non-Transplanted Patients with Chronic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 2031.	1.8	17
375	Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. Annals of Transplantation, 2017, 22, 524-531.	0.5	17
376	Dissociation of glomerular filtration and renal blood flow in HgCl2-induced acute renal failure. Kidney International, 1982, 22, 162-170.	2.6	16
377	No early respiratory benefit with CVVHDF in patients with acute renal failure and acute lung injury. Nephrology Dialysis Transplantation, 2002, 17, 2153-2158.	0.4	16
378	Back to the Future: Middle Molecules, High Flux Membranes, and Optimal Dialysis. Hemodialysis International, 2003, 7, 52-57.	0.4	16

#	Article	IF	CITATIONS
379	Dialysate partitioning in the Genius® batch hemodialysis system: Effect of temperature and solute concentration. Kidney International, 2005, 67, 2470-2476.	2.6	16
380	In vivo distribution and fractionation of indium in rats after subcutaneous and oral administration of [114mln]InAs. Journal of Environmental Monitoring, 2005, 7, 365.	2.1	16
381	Relation between acute kidney injury and multiple-organ failure: The chicken and the egg question*. Critical Care Medicine, 2007, 35, 316-317.	0.4	16
382	Health Implications of Antimicrobial Resistance for Patients With Acute Kidney Injury and Bloodstream Infection. Infection Control and Hospital Epidemiology, 2007, 28, 1107-1110.	1.0	16
383	An Obituary for GFR as the Main Marker for Kidney Function?. Seminars in Dialysis, 2012, 25, 9-14.	0.7	16
384	The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2013, 6, 63-70.	1.4	16
385	Renal replacement therapy: how can we contain the costs?. Lancet, The, 2014, 383, 1783-1785.	6.3	16
386	Prognostic robustness of serum creatinine based AKI definitions in patients with sepsis: a prospective cohort study. BMC Nephrology, 2015, 16, 112.	0.8	16
387	Chronic kidney disease. Clinical Science, 2017, 131, 225-226.	1.8	16
388	A call for harmonization of European kidney care: dialysis reimbursement and distribution of kidney replacement therapies. Nephrology Dialysis Transplantation, 2020, 35, 979-986.	0.4	16
389	Recent Developments in Osmotic Agents for Peritoneal Dialysis. Advances in Chronic Kidney Disease, 1998, 5, 218-231.	2.2	15
390	Peritoneal Dialysis in Anuric Patients: Concerns and Cautions. Seminars in Dialysis, 2002, 15, 305-310.	0.7	15
391	Randomised Long-Term Comparison of Tinzaparin and Dalteparin in Haemodialysis. Clinical Drug Investigation, 2003, 23, 85-97.	1.1	15
392	Goodpasture's syndrome associated with autoimmune thrombotic thrombocytopenic purpura an unusual case. Nephrology Dialysis Transplantation, 2007, 22, 3672-3673.	0.4	15
393	PROGRESS IN UREMIC TOXIN RESEARCH: Phosphate Metabolism in Chronic Kidney Disease: From Pathophysiology to Clinical Management. Seminars in Dialysis, 2009, 22, 357-362.	0.7	15
394	The role of polymer surface degradation and barium sulphate release in the pathogenesis of catheter-related infection. Nephrology Dialysis Transplantation, 2010, 25, 1207-1213.	0.4	15
395	Application of the RIFLE criteria in patients with crush-related acute kidney injury after mass disasters. Nephrology Dialysis Transplantation, 2011, 26, 515-524.	0.4	15
396	Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. Journal of Nephrology, 2014, 27, 707-711.	0.9	15

#	Article	IF	CITATIONS
397	GuÃa de práctica clÃnica sobre el diagnóstico y tratamiento de la hiponatremia. Nefrologia, 2017, 37, 370-380.	0.2	15
398	Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease. Pediatric Nephrology, 2018, 33, 315-323.	0.9	15
399	Initiation of dialysisis the problem solved by NECOSAD?. Nephrology Dialysis Transplantation, 2002, 17, 1550-1552.	0.4	14
400	Behaviour of vanadate and vanadium–transferrin complex on different anion-exchange columns. Application to in vivo 48V-labelled rat serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 775, 143-152.	1.2	14
401	Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. Kidney International, 2003, 63, 732-737.	2.6	14
402	Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population. Nephrology Dialysis Transplantation, 2020, 35, 648-656.	0.4	14
403	Influence of Reuse and of Reuse Sterilants on the Firstâ€Use Syndrome. Artificial Organs, 1987, 11, 137-139.	1.0	13
404	A review of the pathophysiology, causes and prognosis of acute renal failure in the elderly. Geriatric Nephrology and Urology, 1991, 1, 77-91.	0.4	13
405	Application of Kohonen neural networks for the non-morphological distinction between glomerular and tubular renal disease. Nephrology Dialysis Transplantation, 1998, 13, 59-66.	0.4	13
406	Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. Kidney International, 2003, 64, 1365-1373.	2.6	13
407	We don't need no education (Pink Floyd, The Wall ) Multidisciplinary predialysis education programmes: pass or fail?. Nephrology Dialysis Transplantation, 2009, 24, 3277-3279.	0.4	13
408	Development of a MALDI MSâ€based platform for early detection of acute kidney injury. Proteomics - Clinical Applications, 2016, 10, 732-742.	0.8	13
409	Role of the International and National Renal Organizations in Natural Disasters: Strategies for Renal Rescue. Seminars in Nephrology, 2020, 40, 393-407.	0.6	13
410	Measured Glomerular Filtration Rate: The Query for a Workable Golden Standard Technique. Journal of Personalized Medicine, 2021, 11, 949.	1.1	13
411	Transcriptome Analysis in Patients with Chronic Kidney Disease on Hemodialysis Disclosing a Key Role for CD16+CX3CR1+ Monocytes. PLoS ONE, 2015, 10, e0121750.	1.1	13
412	Experience with Continuous Ambulatory Peritoneal Dialysis in Belgium. Peritoneal Dialysis International, 1980, 1, 54-58.	1.1	12
413	Intradialytic Body Weight Changes and Dialyzer Pore Size as Main Contributing Factors to the Evolution of Beta-2-Microglobulin in Dialysis. Blood Purification, 1990, 8, 32-44.	0.9	12
414	Influence of Erythropoietin on Dialyzer Reuse, Heparin Need, and Urea Kinetics in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 1994, 23, 52-59.	2.1	12

#	Article	IF	CITATIONS
415	Relationship Between Biocompatibility and Neutrophil Function in Hemodialysis Patients. Advances in Chronic Kidney Disease, 1996, 3, 312-314.	2.2	12
416	Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids. Nephrology Dialysis Transplantation, 2003, 18, 1648-1653.	0.4	12
417	Acute central haemodynamic effects induced by intraperitoneal glucose instillation. Nephrology Dialysis Transplantation, 2008, 23, 4029-4035.	0.4	12
418	Internal Filtration in a High-Flux Dialyzer Quantified by Mean Transit Time of an Albumin-Bound Indicator. ASAIO Journal, 2013, 59, 505-511.	0.9	12
419	Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. CKJ: Clinical Kidney Journal, 2020, 13, 425-433.	1.4	12
420	Disaster medicine and response: Optimizing life-saving potential. American Journal of Disaster Medicine, 2018, 13, 253-264.	0.1	12
421	Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies. CKJ: Clinical Kidney Journal, 2008, 1, 2-10.	1.4	11
422	Hemodialysis as a Treatment of Severe Accidental Hypothermia. Artificial Organs, 2010, 34, 237-239.	1.0	11
423	Fanconi syndrome in lymphoma patients: report of the first case series. Nephrology Dialysis Transplantation, 2010, 25, 2516-2520.	0.4	11
424	What guidelines should or should not be: implications for guideline production. Nephrology Dialysis Transplantation, 2013, 28, 1980-1984.	0.4	11
425	Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?. Nephrology Dialysis Transplantation, 2016, 31, 1547-1551.	0.4	11
426	HEMO Revisited: Why Kt/Vurea Only Tells Part of the Story. Journal of the American Society of Nephrology: JASN, 2016, 27, 3235-3237.	3.0	11
427	Magnesium and infection risk after kidney transplantation: An observational cohort study. Journal of Infection, 2016, 73, 8-17.	1.7	11
428	Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 10549.	1.8	11
429	Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease. Nephrology Dialysis Transplantation, 2021, 37, 126-138.	0.4	11
430	Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study. PLoS ONE, 2012, 7, e31639.	1.1	11
431	The Dialytic Management of Acute Renal Failure in the Elderly. Seminars in Dialysis, 2002, 15, 127-132.	0.7	10
432	Temperature and concentration distribution within the Genius(R) dialysate container. Nephrology Dialysis Transplantation, 2007, 22, 2962-2969.	0.4	10

#	Article	IF	CITATIONS
433	Vitamin D Binding Protein and the Need for Vitamin D in Hemodialysis Patients. , 2008, 18, 400-407.		10
434	Comparison of Different Methods to Assess Fistula Flow. Blood Purification, 2010, 30, 89-95.	0.9	10
435	Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. Nephrology Dialysis Transplantation, 2010, 25, 2636-2644.	0.4	10
436	How to remove accumulated iodine in burn-injured patients. Nephrology Dialysis Transplantation, 2010, 25, 1614-1620.	0.4	10
437	Home haemodialysis and uraemic toxin removal: does a happy marriage exist?. Nature Reviews Nephrology, 2012, 8, 579-588.	4.1	10
438	Health economics and European Renal Best Practice—is it time to bring health economics into evidence-based guideline production in Europe?. Nephrology Dialysis Transplantation, 2014, 29, 1994-1997.	0.4	10
439	Association of advanced age with concentrations of uraemic toxins in CKD. Journal of Nephrology, 2016, 29, 81-91.	0.9	10
440	<p>Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS</p> . Clinical Epidemiology, 2020, Volume 12, 51-60.	1.5	10
441	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, 23-35.	1.4	10
442	Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Peritoneal Dialysis International, 2008, 28, 142-8.	1.1	10
443	Recombinant Hirudin. BioDrugs, 1999, 11, 417-429.	2.2	9
444	The European Artificial Organ Scene: Present Status. Artificial Organs, 2005, 29, 498-506.	1.0	9
445	Evidence for Internal Filtration in the Genius® System, Performing Slow Low Efficient Daily Dialysis in the Intensive Care Unit. Blood Purification, 2008, 26, 460-467.	0.9	9
446	Role of aortic calcification, stiffness and wave reflections in cardiovascular risk in dialysis patients: Baseline data from the CORD study. Artery Research, 2010, 4, 81.	0.3	9
447	Uremia-Related Oxidative Stress in Leukocytes Is Not Triggered by β2-Microglobulin. , 2013, 23, 456-463.		9
448	Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 3090-3095.	0.4	9
449	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.4	9
450	Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients. Review of the Literature. Mineral and Electrolyte Metabolism, 1999, 25, 324-332.	1.1	8

#	Article	IF	CITATIONS
451	Severe hyponatraemia and hypouricaemia in Gitelman's syndrome. Nephrology Dialysis Transplantation, 2001, 16, 2250-2252.	0.4	8
452	Automated Peritoneal Dialysis Symposium: The Role of APD in the Improvement of Outcomes in an ESRD Program. Seminars in Dialysis, 2002, 15, 422-426.	0.7	8
453	Efficiency of the Genius® Batch Hemodialysis System With Low Serum Solute Concentrations: The Case of Lithium Intoxication Therapy. American Journal of Kidney Diseases, 2005, 46, e95-e99.	2.1	8
454	Disseminated Mycobacterium avium complex infection in a renal transplant patient. European Journal of Internal Medicine, 2005, 16, 53-55.	1.0	8
455	Intervention of the renal disaster relief task force (RDRTF) in the Kashmir earthquake. Nephrology Dialysis Transplantation, 2006, 21, 40-40.	0.4	8
456	Middle Molecules as Uremic Toxins: Still a Viable Hypothesis?. Seminars in Dialysis, 1994, 7, 65-68.	0.7	8
457	The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI. CKJ: Clinical Kidney Journal, 2008, 1, 392-402.	1.4	8
458	The role of the Renal Disaster Relief Task Force. Nature Clinical Practice Nephrology, 2008, 4, 347-347.	2.0	8
459	A tantalizing question: Ferrari or Rolls Royce? A meta-analysis on the ideal renal replacement modality for acute kidney injury at the intensive care unit*. Critical Care Medicine, 2008, 36, 649-650.	0.4	8
460	Chronic nicotine exposure and acute kidney injury: new concepts and experimental evidence. Nephrology Dialysis Transplantation, 2013, 28, 1329-1331.	0.4	8
461	Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin. Nephrology Dialysis Transplantation, 2014, 29, 1092-1096.	0.4	8
462	Introduction: Uremic Toxicity – State of the Art 2014. Seminars in Nephrology, 2014, 34, 85-86.	0.6	8
463	A survey on the methodological processes and policies of renal guideline groups as a first step to harmonize renal guidelines. Nephrology Dialysis Transplantation, 2015, 30, 1066-1074.	0.4	8
464	Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transplant International, 2016, 29, 153-164.	0.8	8
465	A plea for more uremic toxin research in children with chronic kidney disease. Pediatric Nephrology, 2018, 33, 921-924.	0.9	8
466	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. Nephrology Dialysis Transplantation, 2019, 34, 1469-1480.	0.4	8
467	A history of uremic toxicity and of the European Uremic Toxin Work Group (EUTox). CKJ: Clinical Kidney Journal, 2021, 14, 1514-1523.	1.4	8
468	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. Blood Pressure, 2021, 30, 269-281.	0.7	8

#	Article	IF	CITATIONS
469	Effect of gender on various parameters of crush syndrome victims of the Marmara earthquake. Journal of Nephrology, 2004, 17, 399-404.	0.9	8
470	Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality?. Peritoneal Dialysis International, 2006, 26, 429-34.	1.1	8
471	The fate of older diabetic patients on peritoneal dialysis: myths and mysteries and suggestions for further research. Peritoneal Dialysis International, 2007, 27, 611-8.	1.1	8
472	The relation between salt, volume, and hypertension: clinical evidence for forgotten but still valid basic physiology. Peritoneal Dialysis International, 2008, 28, 596-600.	1.1	8
473	Acute renal failure in the elderly. Geriatric Nephrology and Urology, 1999, 9, 153-165.	0.4	7
474	In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs. Nephrology Dialysis Transplantation, 2002, 17, 973-977.	0.4	7
475	The Other Side of the Coin: Impact of Toxin Generation and Nutrition on the Uremic Syndrome. Seminars in Dialysis, 2002, 15, 311-314.	0.7	7
476	Consequences of Using Glucose in Peritoneal Dialysis Fluid. Seminars in Dialysis, 1998, 11, 271-275.	0.7	7
477	The future of European Nephrology 'Guidelines'a declaration of intent by European Renal Best Practice (ERBP). CKJ: Clinical Kidney Journal, 2009, 2, 213-221.	1.4	7
478	PROGRESS IN UREMIC TOXIN RESEARCH: Progress in Uremic Toxin Research: An Introduction. Seminars in Dialysis, 2009, 22, 321-322.	0.7	7
479	When to start chronic dialysis: tunnel vision induced by numbers?. Nephrology Dialysis Transplantation, 2010, 25, 2405-2407.	0.4	7
480	Internal filtration, filtration fraction, and blood flow resistance in high- and low-flux dialyzers. Clinical Hemorheology and Microcirculation, 2014, 58, 455-469.	0.9	7
481	The Reply. American Journal of Medicine, 2014, 127, e15.	0.6	7
482	Haste makes waste—Should current guideline recommendations for initiation of renal replacement therapy for acute kidney injury be changed?. Seminars in Dialysis, 2018, 31, 204-208.	0.7	7
483	Uremic Toxins and Cardiovascular System. Cardiology Clinics, 2021, 39, 307-318.	0.9	7
484	Towards a Rational Screening Strategy for Albuminuria: Results from the Unreferred Renal Insufficiency Trial. PLoS ONE, 2010, 5, e13328.	1.1	7
485	Disaster management of chronic dialysis patients. American Journal of Disaster Medicine, 2007, 2, 96-106.	0.1	7
486	The European Kidney Health Alliance (EKHA) and the Decade of the KidneyTM. Nephrology Dialysis Transplantation, 2023, 38, 1113-1122.	0.4	7

#	Article	IF	CITATIONS
487	Uremic Toxins: Removal with Different Therapies. Hemodialysis International, 2003, 7, 162-167.	0.4	6
488	Clamping of the dialysate outlet line in the Genius® dialysis system does not alter dialysate flow or clearances. Nephrology Dialysis Transplantation, 2006, 21, 1069-1072.	0.4	6
489	Dialysate and Blood Temperature During Hemodialysis: Comparing Isothermic Dialysis With a Singleâ€Pass Batch System. Artificial Organs, 2010, 34, 1132-1137.	1.0	6
490	Thrombotic microangiopathy: A role for magnesium?. Thrombosis and Haemostasis, 2012, 107, 399-408.	1.8	6
491	The Relationship of NT-proBNP and Dialysis Parameters with Outcome of Incident Haemodialysis Patients: Results from the Membrane Permeability Outcome Study. Blood Purification, 2013, 35, 216-223.	0.9	6
492	Clinical Practice Guidelines on diagnosis and treatment of hyponatraemia: response to letter from Otsuka Ltd European Journal of Endocrinology, 2014, 171, L5-L6.	1.9	6
493	Crush Syndrome: A Case Report and Review of the Literature. Journal of Emergency Medicine, 2015, 48, 730-731.	0.3	6
494	Statins for the prevention of contrast-induced acute kidney injury. Current Opinion in Nephrology and Hypertension, 2016, 25, 508-517.	1.0	6
495	Gut-Derived Metabolites and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1311-1313.	2.2	6
496	Funding kidney research as a public health priority: challenges and opportunities. Nephrology Dialysis Transplantation, 2020, , .	0.4	6
497	Health Policy for Dialysis Care in Canada and the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1669-1677.	2.2	6
498	Kidney problems in disaster situations. Nephrologie Et Therapeutique, 2021, 17, S27-S36.	0.2	6
499	Primary Hodgkin's Disease of the Thyroid. Acta Haematologica, 1981, 65, 54-59.	0.7	5
500	Non-ideal behaviour of free vanadate on a Superose 12 size-exclusion column. Application to in vivo 48V-labelled rat spleen homogenate. Biomedical Applications, 2001, 757, 21-29.	1.7	5
501	Fractionation of vanadium in urine of Wistar rats as a function of time after intraperitoneal injection. Journal of Inorganic Biochemistry, 2002, 90, 71-77.	1.5	5
502	THE EPIDEMIC OF CARDIO-VASCULAR DISEASE IN RENAL FAILURE: WHERE DOES IT COME FROM, WHERE DO WE GO?. Acta Clinica Belgica, 2006, 61, 205-211.	0.5	5
503	All high-flux membranes are equal but some high-flux membranes are less equal than others. Nephrology Dialysis Transplantation, 2008, 23, 1481-1483.	0.4	5
504	Defining acute kidney injury: playing hide-and-seek with the unknown man?. Nephrology Dialysis Transplantation, 2011, 26, 399-401.	0.4	5

#	Article	IF	CITATIONS
505	The role of collagen metabolism in CKD-associated arterial senescence: underestimated and underappreciated. Nephrology Dialysis Transplantation, 2011, 26, 2726-2728.	0.4	5
506	Evaluation of Alternatives for Dysfunctional Double Lumen Central Venous Catheters Using a Two-Compartmental Mathematical Model for Different Solutes. International Journal of Artificial Organs, 2013, 36, 17-27.	0.7	5
507	Introduction to the Toxins Special Issue on "Novel Issues in Uremic Toxicityâ€, Toxins, 2018, 10, 388.	1.5	5
508	Single needle hemodialysis: is the past the future?. Journal of Nephrology, 2020, 33, 49-58.	0.9	5
509	Prognostic implications of plasma myoglobin levels in patients with chronic kidney disease. International Journal of Artificial Organs, 2012, 35, 959-968.	0.7	5
510	The impact of healthy start peritoneal dialysis on the evolution of residual renal function and nutrition parameters. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2002, 18, 44-8.	0.1	5
511	The antiâ€proliferative effect of calcitriol on HLâ€60 cells is neutralized by uraemic biological fluids. Nephrology Dialysis Transplantation, 2001, 16, 246-252.	0.4	4
512	CENTRAL VEIN HEMODIALYSIS CATHETERS AND INFECTION: A PLEA FOR TIMELY REFERRAL AND APPROPRIATE HYGIENIC MEASURES. Acta Clinica Belgica, 2003, 58, 342-344.	0.5	4
513	The Patient as a Limit to Dialysis Technology. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2105-2107.	2.2	4
514	Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?. Nephrology Dialysis Transplantation, 2011, 26, 1442-1443.	0.4	4
515	Slow Extended Nocturnal Home Hemodialysis Shows Superior Adequacy Compared to In-Center Dialysis: A Mathematical Analysis. Blood Purification, 2012, 34, 219-224.	0.9	4
516	Less water for haemodialysis: is multiple pass the future pace to go?. Nephrology Dialysis Transplantation, 2012, 27, 3975-3978.	0.4	4
517	Mesothelin Levels in Urine are Affected by Glomerular Leakage and Tubular Reabsorption. Clinical Lung Cancer, 2012, 13, 470-474.	1.1	4
518	EDTAKI: a Nephrology and Public Policy Committee platform call for more European involvement in acute kidney injury. Nephrology Dialysis Transplantation, 2021, , .	0.4	4
519	lsKt/VUrea a Satisfactory Measure for Dosing the Newer Dialysis Regimens?. Seminars in Dialysis, 2001, 14, 12-14.	0.7	4
520	Microalbuminuria is more consistent in the presence of cardiovascular risk factors. Journal of Nephrology, 2013, 26, 580-585.	0.9	4
521	Animal models in peritoneal dialysis: a story of kangaroos and ostriches. Peritoneal Dialysis International, 2006, 26, 571-3.	1.1	4
522	Unipuncture Membrane Plasmapheresis. Artificial Organs, 1983, 7, 365-372.	1.0	3

#	Article	IF	CITATIONS
523	End-stage disease of native kidneys in a patient with biopsy-proven Arndt-Gottron scleromyxoedema and recurrence in the transplanted kidney. Nephrology Dialysis Transplantation, 2007, 22, 3065-3069.	0.4	3
524	<i>Opinion</i> : What Are the Potential Solutions for the Problems with Current Methods for Quantifying Hemodialysis?. Seminars in Dialysis, 2008, 21, 407-409.	0.7	3
525	An infallible recipe? A story of cinnamon, souffle and meta-analysis. Nephrology Dialysis Transplantation, 2008, 23, 2729-2732.	0.4	3
526	Moving ahead on the Kidney Health Initiative innovation roadmap, a transatlantic progress update. Artificial Organs, 2020, 44, 1125-1134.	1.0	3
527	COVID-19 and policy changes for kidney disease: the need for a â€~decade of the kidney'. Nephrology Dialysis Transplantation, 2021, 36, 8-11.	0.4	3
528	The impact of metrological traceability on the validity of creatinine measurement as an index of renal function. Accreditation and Quality Assurance, 2004, 10, 15-19.	0.4	2
529	Approach for guideline development. Nephrology Dialysis Transplantation, 2007, 22, ii1-ii4.	0.4	2
530	There Is Insufficient Evidence That Membrane Incompatibility Causes Amyloidosis. Seminars in Dialysis, 1993, 6, 189-192.	0.7	2
531	Urea Kinetic Modeling: Comparing the Options. Artificial Organs, 2008, 17, 813-816.	1.0	2
532	The ultimate salt war? Uraemic toxins are all that count in dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 62-66.	0.4	2
533	Less water for haemodialysis: is multiple pass the future pace to go?. Nephrology Dialysis Transplantation, 2013, 28, 1067-1070.	0.4	2
534	Should screening of renal markers be recommended in a working population?. International Urology and Nephrology, 2014, 46, 1601-1608.	0.6	2
535	Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia. BANTAO Journal, 2014, 12, 65-74.	0.1	2
536	Type 2 diabetes: a two-headed snake in kidney transplant recipients?. Lancet Diabetes and Endocrinology,the, 2017, 5, 3-5.	5.5	2
537	Further approaches to reduce the cost of renal replacement therapy. Nature Reviews Nephrology, 2017, 13, 720-720.	4.1	2
538	Influence of switching connection ports of double-lumen permanent tunnelled catheters on total solute removal during dialysis. Journal of Nephrology, 2011, 24, 338-344.	0.9	2
539	Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrology Dialysis Transplantation, 2009, 24, 2286-2287.	0.4	1
540	PROGRESS IN UREMIC TOXIN RESEARCH: Conservative Treatment of the Uremic Syndrome. Seminars in Dialysis, 2009, 22, 449-453.	0.7	1

#	Article	IF	CITATIONS
541	Prognostic Implications of Plasma Myoglobin Levels in Patients with Chronic Kidney Disease. International Journal of Artificial Organs, 2012, 35, 959-968.	0.7	1
542	Predicting prognosis in patients with rhabdomyolysis. Nature Reviews Nephrology, 2013, 9, 637-638.	4.1	1
543	FP279HIGH-RESOLUTION PLASMA PROTEOME ANALYSIS IDENTIFIES NEW CHANGES IN MOLECULAR MECHANISMS INVOLVED IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii160-iii161.	0.4	1
544	"Uremic Toxin―Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia. Toxins, 2017, 9, 170.	1.5	1
545	The new European Renal Best Practice guideline on arteriovenous access: why worthwhile to read. Nephrology Dialysis Transplantation, 2019, 34, 1071-1074.	0.4	1
546	Health literacy problems of kidney patients. Nephrology Dialysis Transplantation, 2021, 36, 1155-1157.	0.4	1
547	Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients. Journal of Nephrology, 2013, 26, 119-128.	0.9	1
548	Outcomes of Intermittent Hemodialysis in Critically Ill Patients With Acute Kidney Injury. , 2019, , 960-966.e3.		1
549	Future Directions for Dialysis. Kidney and Dialysis, 2022, 2, 153-162.	0.5	1
550	Membrane plasma exchange in patients with metastatic cancer. Journal of Cancer Research and Clinical Oncology, 1985, 110, 230-233.	1.2	0
551	Reply. Blood Purification, 2001, 19, 71-72.	0.9	0
552	Intermittent Hemodialysis for Acute Renal Failure Patients - An Update. , 2004, 144, 255-263.		0
553	PREDICTION OF DIALYSIS THERAPY FOR ADEQUATE REMOVAL OF UREMIC TOXINS, OTHER THAN UREA. ASAIO Journal, 2005, 51, 58A.	0.9	0
554	ASSESSMENT OF PRESSURE PROFILES IN THE GENIUS?? SYSTEM TO ENHANCE INTERNAL FILTRATION. ASAIO Journal, 2006, 52, 70A.	0.9	0
555	How Should Temporary Vascular Access for Hemodialysis Be Achieved?. Seminars in Dialysis, 1988, 1, 190-191.	0.7	0
556	Should Cuprophane Membranes Continue to Be Used for Chronic Hemodialysis?. Seminars in Dialysis, 1992, 5, 118-120.	0.7	0
557	Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours. CKJ: Clinical Kidney Journal, 2008, 1, 469-470.	1.4	0
558	<i>Correspondence</i> : Dialysate Calcium and the European Best Practice Guidelines on Hemodynamic Instability. Seminars in Dialysis, 2009, 22, 311-311.	0.7	0

#	Article	IF	CITATIONS
559	Encapsulating Peritoneal Sclerosis in a Patient with Primary Hyperoxaluria Type 1: A Case Report. Peritoneal Dialysis International, 2010, 30, 108-111.	1.1	0
560	Uremic Toxins. , 2010, , 219-234.		0
561	Response to Tsikas et al. Comments on Boelaert et al. Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC–MS/MS versus ELISA. Toxins 2016, 8, 149. Toxins, 2016, 8, 312.	1.5	0
562	SP777TAILORED IMMUNOSUPPRESSION IN DE NOVO RENAL TRANSPLANTATION BASED ON IMMUNE FUNCTION MONITORING: A RANDOMISED CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2017, 32, iii406-iii406.	0.4	0
563	SP340IS LOW HEMOGLOBIN AT HEMODIALYSIS INITIATION ASSOCIATED WITH FIRST-YEAR SURVIVAL AMONG PATIENTS TREATED TO TARGET LEVELS SOON AFTER DIALYSIS START?. Nephrology Dialysis Transplantation, 2018, 33, i459-i459.	0.4	0
564	FP318IMPACT OF THE METRIC USED TO DEFINE PROGRESSION OF KIDNEY FAILURE ON THE CONCLUSIONS OF STUDIES. Nephrology Dialysis Transplantation, 2018, 33, i138-i138.	0.4	0
565	FO079CONCENTRATIONS OF P-CRESYL - AND INDOXYL SULFATE AND THEIR PRECURSORS IN DIFFERENT STACES OF CHRONIC KIDNEY DISEASE: FROM FECES TO URINE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
566	SP682THE IMPACT OF DIALYSIS MODALITIES AND REIMBURSEMENT FEES ON PUBLIC HEALTH CARE EXPENDITURE IN EUROPEAN COUNTRIES WITH HIGHER AND LOWER GDPc. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
567	The authors reply. Kidney International, 2020, 98, 784.	2.6	0
568	Prevalence of chronic kidney disease and its risk factors among family practice patients in Lithuania. Clinical Nephrology, 2012, 78, 198-206.	0.4	0
569	Selection of Peritoneal Dialysis as Renal Replacement Therapy. , 0, , 469-477.		Ο